CORT•benzinga•
Corcept Therapeutics Reports Phase 3 ROSELLA Trial Results As Relacorilant Plus Nab-Paclitaxel Improves Survival In Platinum-Resistant Ovarian Cancer Without Added Side Effects, Showing 30% Reduced Progression Risk And 31% Lower Death Risk In ASCO 2025 La
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga